iShares Biotechnology ETF
597 hedge funds and large institutions have $5.25B invested in iShares Biotechnology ETF in 2019 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 128 increasing their positions, 269 reducing their positions, and 96 closing their positions.
3.14% more ownership
Funds ownership: 75.36% → 78.5% (+3.1%)
7% less capital invested
Capital invested by funds: $5.66B → $5.25B (-$401M)
8% less funds holding
Funds holding: 646 → 597 (-49)
28% less call options, than puts
Call options by funds: $509M | Put options by funds: $707M
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
49% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 96
52% less repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 269
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$315M |
| 2 |
Citigroup
New York
|
+$247M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$87.5M |
| 4 |
JP Morgan Chase
New York
|
+$71.2M |
| 5 |
Goldman Sachs
New York
|
+$68.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$380M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$48.7M |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$47M |
| 4 |
LMIM
Lockheed Martin Investment Management
Bethesda,
Maryland
|
-$45.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$42.2M |
IBB Hedge Fund Activity: Q3 2019 in Review
597 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2019, worth a combined $5.25B — down 7.1% from $5.66B a quarter earlier.
Sellers outnumbered buyers: 96 funds closed out of IBB and 49 opened new positions — a net loss of 47 holders — while 269 trimmed existing stakes and 128 added.
The largest buyer was Barclays, adding an estimated $315M. The largest seller was UBS Group, cutting an estimated $380M.
- 597 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2019, down from 646 in Q2 2019.
- Funds reported $5.25B of iShares Biotechnology ETF stock for Q3 2019, down 7.1% quarter-over-quarter.
- 49 funds opened new iShares Biotechnology ETF positions in Q3 2019 and 96 closed out, a net change of -47 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2019 was Barclays, an estimated $315M added.
- The largest iShares Biotechnology ETF seller in Q3 2019 was UBS Group, an estimated $380M sold.
Based on aggregated 13F filings for Q3 2019.